Recruiting studies: Acute Myeloid Leukemia With Npm1 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555 Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3 · 106 location(s) · Kura Oncology, Inc. · NCT07007312 A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · 44 location(s) · Kura Oncology, Inc. · NCT05735184 Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM
Phase 3 · 83 location(s) · Syndax Pharmaceuticals · NCT07211958 Revumenib in Combination With 7+3 + Midostaurin in AML
Phase 1 · 2 location(s) · Richard Stone, MD · NCT06313437 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients Wi
Phase 1 · 1 location(s) · BlueSphere Bio, Inc · NCT07566585 SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurren
Phase 1 · 4 location(s) · Uma Borate · NCT06222580 Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions
Phase N/A · 1 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT07080970 Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06575296 A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leuke
Phase 3 · 253 location(s) · Janssen Research & Development, LLC · NCT06852222 A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Phase 2 · 20 location(s) · Kyowa Kirin Co., Ltd. · NCT07623616 Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
Phase 2 · 18 location(s) · Technische Universität Dresden · NCT05904106 Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Phase 3 · 67 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT06652438 A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patien
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT05886049 MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Phase 1/Phase 2 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06424340 A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1/Phase 2 · 57 location(s) · Syndax Pharmaceuticals · NCT04065399 Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 45 location(s) · Kura Oncology, Inc. · NCT06001788

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.